Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

261. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies

' objectives To obtain estimates of the relative efficacy of three main treatment strategies for attention-deficit hyperactivity disorder (ADHD) in children and youths (aged less than 18 years). Searching The following databases were searched: from 1981 to August 1997, Current Index to Journals in Education (CIJE), HealthSTAR, MEDLINE, and PsycINFO; from 1988 to August 1997, EMBASE; from 1990 to August 1997, OCLC ArticleFirst via FirstSearch; and from 1995 to August 1997 Current Contents. The search terms (...) considered were aged up to 18 years with a diagnosis of attention-deficit disorder (ADD), ADD-hyperactivity, or ADHD made in an explicit and reproducible way with no coexisting diagnosis. Diagnoses were based on the criteria of the American Psychiatric Association (see Other Publications of Related Interest no.1). The age of the participants in the included studies ranged from 4 to 17 years. The proportion of male participants, where stated, ranged from 69 to 100%. Outcomes assessed in the review

1999 DARE.

262. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder

in the treatment of adults with attention-deficit hyperactivity disorder (ADHD). Searching MEDLINE was searched for English language articles (years and search terms not listed). Reference lists of other pertinent studies were scanned. Study selection Study designs of evaluations included in the review Controlled and uncontrolled, retrospective and prospective studies. Open-label and double blind designs were included. Details of whether studies were controlled, and what the control groups were, were unclear (...) for adults with attention-deficit hyperactivity disorder (ADHD). Recent controlled studies suggest that desipramine (an antidepressant) may be as effective as methylphenidate (a stimulant) for improving symptoms of adult ADHD. Although few good controlled studies exist, the available research suggests that certain antidepressants and stimulants are equally effective for adults with ADHD. Antidepressants may offer a safe first-line treatment for adults with ADHD. CRD commentary There are many details

1999 DARE.

263. Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder

and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately following its release at the conference and was updated with the panel’s final revisions. Conclusions Attention deficit hyperactivity disorder or ADHD is a commonly diagnosed behavioral disorder of childhood that represents a costly major public health problem. Children with ADHD have pronounced (...) . Finally, after years of clinical research and experience with ADHD, our knowledge about the cause or causes of ADHD remain largely speculative. Consequently, we have no docu­ mented strategies for the prevention of ADHD. 3 Introduction Attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed behavioral disorder of childhood, estimated to affect 3 to 5 percent of school-age children. Its core symptoms include developmentally inappropriate levels of attention, concentration

1998 NIH Consensus Statements

264. Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis

Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

1996 DARE.

265. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review

Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review Wilens T E, Biederman J, Spencer T J, Prince J Authors' objectives To review the effectiveness and dosing parameters of medication treatment for adult attention deficit/hyperactivity disorder (ADHD). Searching A 'systematic computerised search' was undertaken with search (...) terms including 'hyperactivity', 'hyperkinesis', 'impulsivity', 'attention deficit disorder' and 'attention deficit hyperactivity disorder', cross-referenced with 'adults'. Study selection Study designs of evaluations included in the review Controlled and uncontrolled studies (including retrospective studies) were included. Case reports were excluded unless they contained otherwise unavailable data. Specific interventions included in the review Stimulants (specifically methylphenidate and pemoline

1995 DARE.